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ABST RACT
We aimed at assessing the interaction between visceral adipose tissue (VAT),
insulin resistance (IR), circulating levels of monocyte chemoattractant protein-1
(MCP-1) and malondialdehyde (MDA) and the thyroid parameters in obese
subjects. Methods. Obese subjects without thyroid pathologies or diseases
associated with systemic inflammation and OS were recruited. Insulinemia,
visceral fat thickness, metabolic and thyroid parameters were assayed. Circulating
levels of MCP-1 and MDA were used to quantify inflammation and OS. Results.
A number of 160 obese subjects were included. The MCP-1 level increased with
the degree of obesity and HOMA-IR. MCP 1 was positively associated with antithyroperoxidase antibody (TPOab) levels and the frequency of Hashimoto’s
thyroiditis (HT). The MDA level was positively correlated with the degree of
obesity, aspartate aminotransferase and MCP-1. MDA was an independent
predictor for the occurrence of hypothyroidism. IR patients showed higher fT3
levels and a positive association between insulin and TPOab levels. Conclusions.
Systemic inflammation increased with VAT, IR and OS and was correlated with
the frequency and the severity of HT, suggesting that, in obesity, MCP-1 could be
part of the etiopathogenesis of autoimmune thyroiditis. MDA was an independent
risk factor for hypothyroidism; therefore, redox imbalance associated with obesity
can produce cell damage and thyroid dysfunction. FT3 is increased in IR patients,
thus being a marker for the severity of metabolic impairment.

Introduction
Obesity has become a public health problem with a
highly increased prevalence among adults and children.
Furthermore, the risk of developing a metabolic syndrome
is higher in patients with obesity; metabolic syndrome is
the result of the interplay between an unhealthy lifestyle
and genetic predisposition [1,2].
There is an interconnection between obesity and altered
thyroid function [3]. Thus, patients suffering from obesity
seem to have lower levels of free T4 (fT4) together with a
higher volume of the thyroid gland compared to those with
a body mass index (BMI) within normal limits. Moreover,
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the relationship between thyroid nodules and insulin
resistance (IR) has been established [4]. Several studies
[5,6] have shown that patients with obesity have a high
prevalence of thyroid disorders, although the mechanisms
linking obesity to thyroid pathology are not completely
understood. IR, low-grade systemic chronic inflammation,
and increased oxidative stress (OS) associated with obesity
can directly cause the impairment of thyroid cells and may
trigger factors for autoimmune thyroiditis [7,8].
Additionally, an increased resistance to thyroid
hormones was established in patients suffering from
obesity, a condition which significantly improved after
bariatric surgery together with the improvement of the
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thyrotroph thyroxine resistance index and the thyroidstimulating hormone index [8]. Baseline thyroid
stimulating hormone (TSH) levels might be related to
weight-loss after laparoscopic gastric banding. Thus, the
amount of short-term weight loss after the aforementioned
procedure is greater in patients with low normal TSH than
those with normal and high-normal values [9].
Visceral adipose tissue (VAT) is a significant
determinant of IR vi increased production of
proinflammatory cytokines (leptin, TNFα, IL-6), and
chemokines such as monocyte chemoattractant protein-1
(MCP-1). MCP-1 determines monocytes' recruitment and
their differentiation into macrophages, increasing the
inflammatory cascade and interfering with local and
systemic insulin signaling [10]. Although several studies
have assessed serum MCP-1 levels in patients with fatty
liver [11] or thyroid diseases [12], not enough data have
been reported regarding the effect of "low grade" systemic
inflammation associated with obesity on thyroid morphofunctioning. The interplay between high sensitive-C
reactive protein (hs-CRP) levels and subclinical
hypothyroidism (SH) has also been analyzed in a crosssectional study; however, no association between hs-CRP
and SH was found [13].
It is well-known that both hypothyroidism and
hyperthyroidism determine increased OS, but the
mechanism by which obesity-associated OS may alter the
thyroid remains unclear [14]. IR causes mitochondrial
dysfunction and the activation of microsomal and
peroxisomal oxidation pathways, generating increased
reactive oxygen species (ROS) and lipid peroxidation
products, such as malondialdehyde (MDA) [15].
Mitochondrial dysfunction leads to low cellular energy
reserves and may be involved in the decreased
transmembrane transport of thyroid hormones with
impaired intracellular triiodothyronine (T3) and thyroxine
(T4) levels, which explains the peripheral resistance to
thyroid hormones observed in obesity [16]. Moreover,
MDA may directly cause thyroid damage, having a
systemic proinflammatory and profibrogenic effect
[17,18]. Furthermore, the metabolic dysfunction related to
obesity and IR may alter the deiodinase-1 activity with
decreased intracellular T4-to-T3 conversion and
intracellular T3 levels, and increased deiodinase-3
expression, which stimulates T4 conversion to the inactive
rT3 form, responsible for the occurrence of the “low T3”
syndrome [19-21].
Based on the hypothesis that IR, inflammation and OS
associated with obesity could be involved in the
etiopathogenesis of thyroid disorders, this study assesses
the interaction between metabolic markers, serum MCP1&MDA levels and thyroid parameters in subjects with
obesity. Our research's second objective was to divide the
140

subjects with obesity at a cut-off HOMA-IR ≥ 2.5 and
compare IR to non-IR groups in terms of inflammation,
redox imbalance, and thyroid parameters, considering IR
as a marker of severe metabolic impairment.
Our study's novelty consists of the complex, integrative
analyses of the associations between metabolic markers,
systemic inflammation, OS and thyroid parameters, and
their evaluation as possible risk factors for the changes in
thyroid morpho-functioning, commonly observed in
subjects with obesity.

Materials and Methods
A cross-sectional, observational study was conducted
with the recruitment of eligible subjects, using a nonprobabilistic sampling method, i.e. convenient sampling.
Patients with obesity, presenting from November 2015 to
December 2017 to the Endocrinology outpatient clinic for
obesity investigation, were consecutively enrolled.
Subjects aged >18 years and with a BMI ≥ 30 kg/m2 were
included in the sample. Patients with previously known
thyroid disorders or diseases associated with increased
systemic inflammation and OS, including diabetes
mellitus, depression, epilepsy, schizophrenia, cancer,
rheumatoid arthritis, decompensated liver disease,
congestive heart failure, or chronic renal failure were
excluded.
Each patient was informed before recruitment
regarding the protocol and was asked for written consent in
order to participate in the study. The study protocol was
approved by the Ethics Committee of “Iuliu Haţieganu”
University of Medicine and Pharmacy and aligned with the
ethical principles in the Declaration of Helsinki.
All participants underwent clinical, laboratory and
ultrasound assessments.
Clinical evaluation
Demographic (gender, age) data and the
anthropometric data, weight, height, waist circumference
(WC) of each participant, were measured and recorded.
BMI was calculated as the ratio between weight/height2
(kg/m2). Obesity was considered at BMI values ≥30 kg/m2
and was classified as degree I (30-34.9 kg/m2), II (35-39.9
kg/m2), or III (BMI ≥40 kg/m2) [22]. The diagnosis of
abdominal obesity was established at WC ≥80 cm in
women and ≥94 cm in men [23]. The same examiner
performed all the measurements.
Laboratory investigations
Blood samples were collected in the morning after
overnight fasting. The biochemical determinations
(glycemia, aspartate aminotransferase [AST], alanine
aminotransferase [ALT], gamma-glutamyl transpeptidase
[GGT], triglycerides [TG], total cholesterol [TC], HDL-
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cholesterol, and LDL-cholesterol) were performed on an
automated analyzer (Beckman Coulter Unicell DXC600,
USA), using specific commercially available kits. Basal
insulinemia was determined on an automatic analyzer
(Beckman Coulter Unicell DXI600, USA) by
chemiluminescence method (CMIA), using a specific kit
with the serum detection range from 1.9 μIU/mL to 23
μIU/mL. IR was assessed with the homeostatic model
assessment IR (HOMA-IR) index, using the following
formula: HOMA-IR = basal glycemia (mg/dL) × basal
insulinemia (μIU/mL)/405. A HOMA-IR index ≥2.5 was
considered as a criterion for IR [24,25]. At this threshold
value, the study group was divided into two subgroups:
obese-IR (HOMA-IR≥2.5) and obese non-IR (HOMAIR<2.5) and were compared in terms of metabolic
impairment, inflammation, redox imbalance, and thyroid
parameters.
The TSH, fT4, free T3 [fT3], anti-thyroperoxidase
antibody [TPOab], and anti-thyroglobulin antibody [TGab]
were evaluated by ELISA on an automated analyzer
(Beckman Coulter Unicel DXI 600, USA) and specific kits.
The fT3/fT4 ratio was subsequently calculated and not
directly determined. The serum MCP-1 as a marker of
inflammation was measured on a semi-automated analyzer
(Tecan Trading AG, Switzerland), using the quantitative
sandwich ELISA method and protocol described in the kit
with a serum detection range from 31.25 pg/ml to 2,000
pg/ml. The plasma MDA was measured as a marker of OS,
using
an
isocratic
high-performance
liquid
chromatography (HPLC) method based on fluorescence
detection (Shimadzu LC 2010 Chromatographic System)
and a specific kit (Chromsystems Instruments & Chemicals
GmbH, Germany). The limit of detection (7.752×10-4
μmol/L) and quantification (15.48×10-4 μmol/L) was
determined using the SMAC program.
Ultrasound evaluation
The measurement of the abdominal subcutaneous fat
thickness (SFT, cm) and visceral fat thickness (VFT, cm)
was performed in all patients using Mindray DC-N3
Doppler ultrasound with a 5-MHz convex probe. VFT is
considered a reliable indicator of VAT and was measured
with the probe located 1 cm above the navel, on the
xiphoid-umbilical line, both longitudinally and
transversally, and defined as the distance between the
white line and the anterior aortic wall, while SFT was
measured as the distance between the white line and the
skin [26]. The ultrasound evaluation was performed by the
same radiologist, who was blinded to the study.
Statistical analysis
Statistical analysis was done with Statistics (StatSoft
v.8, USA). Qualitative data are reported as absolute and
relative frequencies (%) with 95% confidence interval

bounds using an exact method [27] provided in squared
brackets (CI). The Shapiro-Wilk test was applied to assess
the normality of the measurements and the data were
expressed as mean (SD=standard deviation) for normally
distributed data, and median and interquartile range
(quartile 1 to quartile 3) otherwise. The association
between the qualitative data was tested with the Chi-square
test. The comparison between two independent groups was
performed using Student’s t-test for normally distributed
data, and Mann-Whitney test otherwise. The comparisons
between more than two groups were performed with the
Kruskal-Wallis test. The association between variables was
evaluated using the Spearman correlation coefficient. Pvalues <0.05 were considered significant for the
comparison between two groups and 0.017 for the
comparison between three groups. Logistic regression
analysis was used to test univariate and multivariate
associations, and the OR (odds ratio) with associated 95%
confidence intervals were reported.

Results
One hundred and sixty patients with a mean age of
45±12.44 years (range 18–68 years) were included in the
study. The majority of patients were women (91.25%
[85.63 to 95.00]). Most frequently, patients were obesity
degree I (65% [56.88 to 72.50]), while obesity degree II
was observed in 21.25% [15.00 to 28.12] and degree III in
13.75% [8.75 to 20.00]. The frequency of IR (HOMAIR≥2.5) was 53.75% [45.63 to 61.87]. The prevalence of
thyroid dysfunction in the studied group was 18.12%, as
follows: 0.625% had hyperthyroidism and 17.5% had
hypothyroidism. Autoimmune and non-autoimmune
hypothyroidism affected 12% and 5.5% of the patients,
respectively. Hashimoto's thyroiditis (HT) was present in
24.5% of the patients.
The summary of the investigated clinical, thyroid,
metabolic, inflammatory, and OS parameters is presented
in Table 1.
Metabolic and thyroid parameters
A low correlation was identified between the degree of
obesity (BMI) and the degree of hepatic impairment
expressed by the GGT level and TSH on the one hand, and
some blood markers, on the other hand (Table 2). Moderate
correlations of VFT with some blood markers were also
identified (Table 2).
Although the frequency of thyroid disorders increased
with the degree of obesity (degree I: 27.88%, degree II:
35.29%, degree III: 36.36%), no significant differences
between the degrees of obesity and the presence of thyroid
dysfunction or HT were identified (p > 0.5).
As expected, the values of VFT (Kruskal-Wallis test:
19.67, p=0.0001) were significantly different between
patients with different degrees of obesity (Figure 1).
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Table 1. Clinical, biochemical, thyroid, inflammatory status, oxidative stress, and ultrasound parameters in the study
group
Parameter

Value

Parameter

Demographic and clinical
Age (years)

a

BMI (kg/m )
WC (cm)
HC (cm)

Biochemical
ALT (IU/L)b

45 (12.44)

2 b

34 (31.83 to 36.88)

a

AST (IU/L)

108 (11.70)

b

Value

22 (17.00 to 29.25)

b

20 (18.00 to 24.00)
a

203 (43.53)

a

130 (30.98)

a

47 (10.11)

Total cholesterol (mg/dL)

110 (106 to 117.25)

LDL-cholesterol (mg/dL)

HDL-cholesterol (mg/dL)
TSH (µIU/mL)b
fT4 (ng/mL)

a

fT3 (ng/mL)

a

0.79 (0.13)

fT3/fT4ratio(ng/mL)
TPOab (IU/mL)

Insulin (µIU/mL)a

1.81 (1.20 to 2.67)

b

b

TGab (IU/mL)b

Glycemia (mg/dL)

a

98 (9.87)

a

0.32 (0.04)

HOMA-IR

0.40 (0.36 to 0.46)

Ultrasound

0.95 (0.40 to 5.35)

SFT (cm)b

2.7 (2.5 to 2.98)

0.35 (0.20 to 0.70)

VFT (cm)a

5.17 (1.03)

Inflammatory status
MCP-1 (pg/mL)

12 (6.71)
a

2.99 (1.68)

Oxidative stress

b

MDA (µmol/L)b

31 (24.21 to 56.50)

b

mean (standard deviation)

0.11 (0.07to 0.15)

median (quartile 1 to quartile 3)

Abbreviations: BMI - body mass index, WC - waist circumference, HC - hip circumference, TSH – thyroidstimulating hormone, fT4 - free thyroxine, fT3 - free triiodothyronine, TPOab – anti-thyroperoxidase antibodies,
TGab – anti-thyroglobulin antibodies, ALT - alanine aminotransferase, AST - aspartate aminotransferase, GGT
- gamma-glutamyl transpeptidase, TG - triglycerides, LDL-cholesterol - low-density lipoprotein cholesterol,
HDL-cholesterol - high-density lipoprotein cholesterol, HOMA-IR - homeostatic model assessment insulin
resistance index, SFT - subcutaneous fat thickness, VFT - visceral fat thickness, MCP-1 - serum monocyte
chemoattractant protein-1, MDA - malondialdehyde.
Table 2. Degree of obesity, VFT, GGT and TSH
significant correlations with blood markers
Spearman
correlation
coefficient

P-value

Degree of obesity
&
0.377
0.0001
HOMA-IR
0.172
0.03
ALT
0.238
0.002
GGT
0.17
0.03
TG
VFT &
WC
0.432
<0.001
insulinemia
0.402
0.005
HOMA-IR
0.433
0.040
GGT &
fT4
0.23
0.003
fT3/fT4
-0.19
0.014
TSH &
TC
0.16
0.042
Abbreviations: HOMA-IR - homeostatic model
assessment insulin resistance index, ALT - alanine
aminotransferase,
GGT
gamma-glutamyl
transpeptidase, TG - triglycerides, VFT - visceral fat
thickness, WC - waist circumference, fT4 - free
thyroxine, fT3 - free triiodothyronine, TSH – thyroidstimulating hormone, TC - total cholesterol.
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Table 3. Significant Spearman correlations between
serum MCP-1, MDA and clinical, metabolic,
inflammatory status, oxidative stress and thyroid
parameters
Parameter

MCP 1

MDA

ρ

P

ρ

p

BMI (kg/m2)

0.286

0.0002

0.194

0.01

Obesity degree

0.268

0.0006

0.140

0.07

WC (cm)

0.164

0.03

0.174

0.02

VFT (cm)

0.674

<0.001

-0.042

0.59

Insulin (µIU/mL)

0.150

0.05

0.049

0.53

HOMA-IR ≥ 2.5

-0.182

0.02

-0.034

0.66

TG (mg/dL)

0.306

0.0001

0.155

0.049

AST (IU/L)

0.039

0.62

0.222

0.005

TPOab (IU/mL)

0.198

0.012

0.115

0.14

HT

0.173

0.028

0.110

0.16

MDA (µmol/L)
0.207
0.008
Abbreviations: BMI - body mass index, WC - waist
circumference, VFT - visceral fat thickness, HOMAIR - homeostatic model assessment insulin resistance
index, TG - triglycerides, AST - aspartate
aminotransferase, TPOab - antithyroperoxidase
antibodies, HT - Hashimoto’s thyroiditis, MDA malondialdehyde.
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Systemic inflammation and OS
The serum MCP-1 level correlated positively with BMI
(Table 3) and increased with the degrees of obesity
(Kruskal-Wallis test: 12.24, p=0.002) (Figure 2).
Moreover, serum MCP-1 level increased with
abdominal obesity (WC), TG level (Table 3) and at a cutoff HOMA-IR ≥2.5, serum MCP-1 levels were higher in
IR versus non-IR patients (Table 3).
Regarding the association between thyroid parameters,
serum MCP-1 level correlated significantly with the level
of TPOab and the frequency of HT (Table 3).

A tendency for an association between MCP-1 and
Hashimoto's thyroiditis was evident in the logistic
regression analysis (CI95% [1.000-1005]; p = 0.071).
The OS's assessment in the study group revealed that
serum MDA level increased with BMI and WC, TG, and
AST, and positively correlated with the systemic
inflammation expressed by MCP-1 (Table 3).
Moreover, multiple regression analysis showed that
MDA is an independent risk factor associated with the
presence of hypothyroidism (CI95% [1.082-781.39]; p =
0.045).

Figure 1. The variability of visceral fat thickness
according to the degree of obesity. The middle line
represents the median value, the lower line is given
by the value of the first quartile, and the upper line
represents the value of the third quartile.

Figure 2. The variability of serum monocyte
chemoattractant protein-1 (MCP-1) according to the degrees
of obesity. The middle line represents the median value, the
lower line is given by the value of the first quartile, and the
upper line represents the value of the third quartile.

Comparison between the IR and non-IR group at
cut-off HOMA-IR ≥ 2.5
The group with obesity was divided according to
HOMA-IR ≥ 2.5 in order to analyze the differences
between the groups regarding the metabolic impairment,
the systemic inflammation, OS and the changes in thyroid
parameters at this threshold value of IR. Table 4 shows the
differences between IR and non-IR patients.
Factors significantly associated with IR in the
univariate analysis included obesity (both in terms of
degree [BMI] and distribution [WC, VFT]), ALT, GGT,
and hypertriglyceridemia (Table 4), but the multiple linear
regression analysis established that only ALT (CI95%
[1.008-1.074], p=0.01) and VFT (CI95% [1.167-2.331],
p=0.005) were independent factors associated with IR.
Additionally, IR patients showed significantly higher

serum MCP-1 levels than non-IR ones, but no significant
difference was noticed regarding the MDA level (Table 4).
Hypothyroidism had a higher frequency of 19.76%
(n=17) in IR patients versus non-IR patients 14.86%
(n=11), but the difference did not reach the statistical
significance threshold (p>0.05). One of the non-IR patients
had hyperthyroidism, while 23% of the IR and 26% of the
non-IR patients had HT (p=0.72).
As shown in Table 4, IR patients showed significantly
higher fT3 levels than non-IR patients. Moreover,
insulinemia was positively associated with TPOab level
(ρ=0.21, p=0.048) and serum fT4 levels correlated
negatively with TG levels (ρ=-0.2483, p=0.0212) in IRpatients.
In the regression analysis, IR proved not to be a risk
factor for thyroid dysfunction.

Table 4. Clinical, metabolic, inflammatory status, oxidative stress and thyroid parameters according to
the presence of insulin resistance (IR)
HOMA-IR ≥ 2.5 (n=86)

HOMA-IR < 2.5 (n=74)

P

Age (years) a

46 (12.38)

44 (12.47)

0.23

BMI (kg/m2) b

35 (32.90 to 38.44)

32 (31.05 to 34.40)

<0.0001

111 (12.39)

104 (9.80)

0.0003

2.8 (2.64 to 3.15)

2.60 (2.40 to 2.80)

<0.0001

5.43 (0.96)

4.86 (1.02)

0.0004

WC (cm)

a

SFT (cm) b
VFT (cm)

a
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ALT (IU/L) b

24 (18.00 to 35.75)

19 (16.00 to 25.00)

0.001

b

20 (18.00 to 25.00)

20 (17.25 to 23.00)

0.20

19 (16.00 to 28.75)

16 (12.00 to 21.00)

0.002

AST (IU/L)

GGT (IU/L) b
TG (mg/dL) b

139 (116.50 to 169.75)

119 (88.50 to 144.75)

0.005

a

206 (49.20)

200 (35.89)

0.37

LDL-cholesterol (mg/dL) a

133 (32.96)

126 (28.29)

0.16

46 (10.58)

47 (9.60)

0.93

36 (24.90 to 65.89)

27 (23.75 to 39.78)

0.021

0.11 (0.08 to 0.16)

0.11 (0.07to 0.14)

0.66

1.97 (1.30 to 2.68)

1.74 (1.09 to 2.60)

0.21

fT4 (ng/mL) b

0.80 (0.13)

0.78 (0.12)

0.26

fT3 (ng/mL) b

0.32 (0.04)

0.28 (0.02)

0.029

0.40 (0.36 to 0.45)

0.40 (0.36 to 0.47)

0.83

0.70 (0.40 to 2.85)

1.00 (0.40 to 5.50)

0.66

0.30 (0.10 to 0.50)

0.40 (0.20 to 0.98)

0.14

Total cholesterol (mg/dL)

HDL-cholesterol (mg/dL)
MCP-1(pg/mL)

a

MDA (µmol/L)
TSH (µIU/mL)

fT3/fT4 ratio

a

a

TPOab (IU/mL) a
TGab (IU/mL)
a

a

a

mean (standard deviation), Student’s t test for independent samples
median (quartile 1 to quartile 3), Mann-Whitney test
Abbreviations: BMI - body mass index, WC - waist circumference, SFT - subcutaneous fat
thickness, VFT - visceral fat thickness, ALT - alanine aminotransferase, AST - aspartate
aminotransferase, GGT - gamma-glutamyl transpeptidase, TG - triglycerides, LDL-cholesterol low-density lipoprotein cholesterol, HDL-cholesterol - high-density lipoprotein cholesterol, MCP-1
- serum monocyte chemoattractant protein-1, MDA - malondialdehyde, TSH - thyroid-stimulating
hormone, fT4 - free thyroxine, fT3 - free triiodothyronine, TPOab - anti-thyroperoxidase antibodies,
TGab - anti-thyroglobulin antibodies.

b

Discussions
One of the main findings of our study was that systemic
inflammation (MCP-1) increased significantly with the
obesity degree (BMI), abdominal distribution (VFT, WC),
and IR. It was also significantly positively correlated with
the severity (TPOab) and frequency of Hashimoto’s
thyroiditis in subjects with obesity. In addition, the OS
expressed by MDA increased significantly with systemic
inflammation and it was a predictive factor associated with
the presence of hypothyroidism in the study group of
patients with obesity.
These results are consistent with the literature data
reported and support the idea that increased serum MCP-1
in patients with obesity may be a direct consequence of
abdominal obesity and IR [28,29]. The relationship
between obesity, fT4, MCP-1 and nerve growth factor-β
(NGF-β) was investigated in a recent study conducted by
Molnár exclusively on women [30] which demonstrated
the correlation between high MCP-1, NGF-β levels and
low serum fT4 levels in women with obesity [30].
Likewise, Sartipy et al. revealed increased microRNA
MCP-1 expression at VAT and an increase of MCP-1 level
after the induction of hyperinsulinemic status both in vitro
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and in vivo, showing that visceral obesity and IR are the
causes of increased MCP-1 serum levels [29]. Moreover,
systemic inflammation triggers altered insulin response,
making IR both the cause and the effect of systemic
inflammation in obesity [11,31].
Regarding the low-grade inflammation associated with
obesity and the possible thyroid involvement, our study
revealed a significant correlation between MCP-1 and both
severity (TPOab level) and HT's frequency in patients with
obesity, but without any significant association with the
thyroid function. Although there were no significant
differences between IR versus non-IR patients regarding
the frequency of HT, a significant correlation between
insulinemia and TPOab levels was seen in IR versus nonIR patients, indicating the possible pathogenetic
contribution of hyperinsulinism in the production of
autoantibodies. Several studies support the role of
inflammatory cytokines in HT etiopathogenesis; MCP-1
and other cytokines (TNFα, IL-1, INFδ) may induce and
aggravate autoimmune thyroid diseases through leukocyte
chemotaxis and the perpetuation of a chronic inflammatory
response, leading to thyroid cell injury and impaired
functioning [7,32]. Several researchers [33-35] have
shown that hyperleptinemia associated with VAT
accumulation may be a pathogenic link between obesity,

Insulin resistance, inflammation, redox imbalance and the thyroid in obese subjects

immune system changes, and HT by activating the
inflammatory induction signals in susceptible patients. Our
study's result is consistent with that of Kokkotou et al. [12],
which revealed a positive correlation between MCP-1 and
antithyroid antibodies in HT patients without reporting a
significant association with the thyroid function.
Inflammation and OS are closely related processes in
obesity, and both interfere with insulin signaling,
modifying the synthesis, activity, and metabolism of
thyroid hormones [17-19,21]. Our study showed a
significant association between MDA and the obesity
degree & distribution (BMI, WC), along with the hepatic
impairment (AST) and its significant increase with
systemic inflammation (MCP-1). Instead, no significant
difference was found in MDA levels related to IR, probably
because most patients had degree I obesity, which is not
associated with a significant increase in OS or IR. In
regression analyses, MDA was an independent factor
associated with hypothyroidism in the studied obesity
group.
The possible mechanism by which OS may alter the
thyroid function is complex. The balance between oxidants
and antioxidants is critical for the proper functioning of the
thyroid gland, and the direct effect of increased ROS in
thyroid diseases has been investigated by several studies
[36]. Moreover, reduced cellular energy production
secondary to mitochondrial dysfunction is associated with
the decreased transportation of thyroid hormones to the
cells, leading to the intracellular deficiency of thyroid
hormones. Redox imbalance can also alter the expression
and the activity of deiodinases with decreased intracellular
activation of T4 in T3 and increased production of
reversed-T3, resulting in “low-T3” syndrome [16].
Along with the adipose tissue, the liver is the main
source of ROS in obesity. The increased influx of FFA and
inflammatory cytokines into the portal vein from VAT
lipolysis may cause mitochondrial liver dysfunction,
increased ROS release, promoting necroinflammation and
aggravating IR, resulting in fatty liver disease (HS/NASH)
[37].
The synthesis of thyroid hormone-binding proteins and
the activation of T4 into T3 (by deiodinase-1) occur in the
liver, and thus liver dysfunction associated with the
severity of obesity and IR might influence hepatic T3
output by altering the transportation of the thyroid
hormones to the cellular level and their feedback at the
hypothalamic-pituitary level [38,39]. In this respect, our
study revealed a significant positive correlation between
GGT and serum fT4 levels and a negative correlation
between GGT levels and fT3/fT4 ratio. Moreover, GGT
levels increased with IR and obesity degree and
represented cellular response expression against OS
[40,41]. Along with the positive association between OS
(MDA) and AST, this supports the effect of liver

dysfunction on changes in the thyroid parameters observed
in obesity.
Regarding the frequency of thyroid dysfunction
(18.12%) or HT (24.5%), our results are consistent with the
literature data for patients with obesity [35,42,43], but
unlike other studies [5,6,34,38] we found no significant
differences between the degrees of obesity according to the
IR presence, possibly due to the predominance of degree I
obesity, which is not accompanied by marked metabolic
and endocrine changes.
Consistent with other studies suggesting that fT3 and/or
fT3/fT4 ratio increase are markers for the severity of
metabolic damage in patients with obesity, our study
results show that IR patients exhibited significantly higher
fT3 levels than non-IR patients. Furthermore, serum TG
level was significantly higher in IR patients and associated
with increased VFT and systemic inflammation (MCP-1)
(which is explained by VAT lipolysis due to IR) and
negatively correlated with fT4 levels as compared to nonIR ones. These results are most likely secondary to
increased deiodinase-2 activity at the VAT level, with
higher conversion of T4 to T3. The increase in local T3
production is probably a defense mechanism to limit
further adipose gain by increasing thermogenesis and
stimulating the metabolic activity [20].
Concerning the association between the thyroid and
lipid parameters, our study highlighted a significant
positive correlation between serum TSH and cholesterol
levels, as hypothyroidism decreases the rate of lipoprotein
degradation and LDL-cholesterol receptor synthesis. Other
studies reported similar results regarding the association
between thyroid hormones and metabolic parameters,
predictive for the severity of the metabolic impairment
[33,37,42-44].
Study limitations
Our study's main limitation is the applied nonprobabilistic sampling method that led to the unequal
distribution of genders in the investigated sample, since it
is known that women seek medical attention more
frequently than men. Notwithstanding, the existing data in
the literature demonstrated the predominance of thyroid
disorders among the female population [45]. Thus, there
are a considerable number of studies that have been carried
out on female population alone [30, 46]. A more accurate
view could be obtained by investigating subjects with
obesity from the general population rather than those who
presented for medical consultations.

Conclusions
Systemic inflammation increased with visceral
adiposity, IR, and was significantly correlated with the
frequency and the severity (TPOab levels) of HT,
suggesting that, in obesity, MCP-1 could be part of the
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etiopathogenesis of autoimmune thyroiditis. OS (MDA)
increased significantly with systemic inflammation (MCP1) and it was an independent risk factor for the occurrence
of hypothyroidism, sustaining that redox imbalance
associated with obesity can produce cell damage and
contribute to the pathophysiology of thyroid dysfunction.
A significantly increased level of fT3 in insulin-resistant
vs. non-insulin-resistant patients supports the value of fT3
as a marker for the severity of metabolic impairments in
patients with obesity.
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